Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Jul;58(7):961-963.
doi: 10.1007/s40262-019-00781-1.

Authors' Reply to Nicolas: "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"

Didier Concordet  1 , Peggy Gandia  1 , Jean-Louis Montastruc  2 , Alain Bousquet-Mélou  1 , Peter Lees  3 , Aude A Ferran  1 , Pierre-Louis Toutain  4   5
Affiliations
Comment

Authors' Reply to Nicolas: "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"

Didier Concordet et al. Clin Pharmacokinet. 2019 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Didier Concordet, Peggy Gandia, Jean-Louis Montastruc, Alain Bousquet-Mélou, Peter Lees, Aude A. Ferran, and Pierre-Louis Toutain have no conflicts of interest that are directly relevant to the content of this reply.

Comment on

References

    1. Nicolas P. Comment on: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients? Clin Pharmacokinet. 2019 doi: 10.1007/s40262-019-00778-w. - DOI - PubMed
    1. Concordet D, Gandia P, Montastruc J-L, Bousquet-Mélou A, Lees P, Ferran A, et al. Levothyrox® new and old formulations: are they switchable for millions of patients? Clin Pharmacokinet. 2019 doi: 10.1007/s40262-019-00747-3. - DOI - PMC - PubMed
    1. Sauter R, Steinijans VW, Diletti E, Böhm A, Schulz HU. Presentation of results from bioequivalence studies. Int J Clin Pharmacol Ther Toxicol. 1992;30:233–256. - PubMed
    1. Chen ML, Patnaik R, Hauck WW, Schuirmann DJ, Hyslop T, Williams R. An individual bioequivalence criterion: regulatory considerations. Stat Med. 2000;19:2821–2842. doi: 10.1002/1097-0258(20001030)19:20<2821::AID-SIM548>3.0.CO;2-L. - DOI - PubMed
    1. Endrenyi L, Amidon GL, Midha KK, Skelly JP. Individual bioequivalence: attractive in principle, difficult in practice. Pharm Res. 1998;15:1321–1325. doi: 10.1023/A:1011972732530. - DOI - PubMed

LinkOut - more resources